YKL-40:彻底改变了肝移植中的心脏风险预测和治疗方法
Ileana Lulic1,2, Dinka Lulic3,4, Ivan Durekovic1
1Department of Anesthesiology, Intensive Care and Pain Medicine, Clinical Hospital Merkur, Zagreb 10000, Croatia.
World journal of transplantation
|December 8, 2025
概括
生物标志物YKL-40在预测肝移植 (LT) 患者心血管风险方面表现有前途. 将YKL-40集成到风险模型中可以改善患者的选择和护理.
科学领域:
- 生物医学研究的研究.
- 心血管医学 心血管医学
- 移植科学 移植科学
背景情况:
- 心血管并发症是肝移植 (LT) 中的主要死亡原因.
- 目前对LT患者的风险评估策略存在局限性.
- 一种糖蛋白YKL-40与炎症,内皮功能障碍和纤维化有关.
研究的目的:
- 探索YKL-40作为LT患者心血管风险生物标志物的潜力.
- 讨论将YKL-40纳入LT接受者的心血管评估框架.
- 概述LT护理中YKL-40的翻译研究方向.
主要方法:
- 对YKL-40的现有文献的审查,心血管并发症和肝移植.
- 对YKL-40在血管损伤和心肌功能障碍 (NF-κB,STAT3信号传递) 中提出的机制的分析.
- 讨论YKL-40在预测模型中的潜在作用,包括人工智能支持的方法.
主要成果:
- YKL-40与不良的心血管结果和肝脏疾病严重程度有关.
- YKL-40在血管损伤和心肌功能障碍中起作用.
- 目前,YKL-40正在为LT的心血管风险调节进行研究.
结论:
- 在肝移植中,YKL-40显示出改善心血管风险分层的潜力.
- 将YKL-40集成到风险模型中可以提高高风险LT接受者的早期识别.
- 进一步的研究和YKL-40的临床采用可能会导致精确指导的LT护理.
相关概念视频
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
169
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
169
Kidney Transplant I: Introduction
310
A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
310
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
203
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
203
Coronary Artery Disease IV: Preventive Measures
575
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
575
Atherosclerosis III: Management
296
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
296
Liver Physiology
3.4K
The liver, an essential organ in the human body, performs over 200 vital functions that can be broadly categorized into metabolic, hematological, endocrine regulation, and bile production.
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of 70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can...
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of 70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can...
3.4K


